Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PAN-301-1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PAN-301-1 (SNS-301) Vaccine | EXPERIMENTAL | PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days |
| Name | Type | Description |
|---|---|---|
| PAN-301-1 | BIOLOGICAL | - |
Inclusion Criteria: 1. Signed and dated written Ethics Committee approved informed consent 2. Men aged 21 to 85 years with a histologic diagnosis of prostate cancer with a biochemical relapse following definitive local therapy (RP or radiation therapy) 3. Patients are not eligible or are unwilling ...
Top 20 of 54 competitors
PAN-301-1 is an investigational monoclonal antibody being studied for the treatment of prostate cancer. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a Phase 1 clinical trial to assess its safety and tolerability in patients with prostate cancer.
The specific molecular target of PAN-301-1 has not been disclosed in available information. As a monoclonal antibody, it is designed to bind to a specific antigen, but the exact target is not publicly detailed. Further research and clinical data may reveal the precise mechanism of action.
PAN-301-1 is being developed by Sensei Biotherapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's potential in treating prostate cancer. Sensei Biotherapeutics is focused on advancing innovative immunotherapies for cancer patients.
PAN-301-1 is in Phase 1 clinical development. A Phase 1 trial has been completed, involving 12 patients with prostate cancer. The drug is still investigational and has not received FDA approval. Further clinical studies would be needed to establish its safety and efficacy.
PAN-301-1 has been studied in a Phase 1 clinical trial registered as NCT03120832. This trial, titled 'Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients,' was conducted in the United States and has been completed. The study enrolled 12 male patients with prostate cancer, aged 21 years and older.
Yes, PAN-301-1 is also known as SNS-301. The clinical trial NCT03120832 refers to the drug as PAN-301-1 (SNS-301), indicating that both names are used interchangeably for the same investigational monoclonal antibody being developed for prostate cancer.